India is increasingly becoming a preferred destination for the global pharmaceutical supply chain, according to a recent report by Macquarie. The country’s strong manufacturing capabilities, cost efficiency, and regulatory reforms are driving its growth in the sector. The report highlights that India’s pharmaceutical industry, already valued at over $50 billion, is poised for further expansion as global companies seek to reduce dependence on China. With a well-established ecosystem of raw material suppliers, skilled workforce, and world-class production facilities, India offers a competitive edge in active pharmaceutical ingredients (APIs) and generic medicines. Government initiatives such as the Production-Linked Incentive (PLI) scheme and policy support for domestic API production have further strengthened India’s position. Additionally, rising investments in research and development (R&D) and the adoption of advanced technologies, including AI-driven drug discovery and digital healthcare solutions, are making India an attractive hub for global pharma giants. With increasing partnerships, export growth, and a favorable policy landscape, India is set to play a crucial role in ensuring a resilient and diversified global pharmaceutical supply chain. As multinational firms continue to shift their sourcing strategies, India stands out as a key beneficiary of this transformation. #PharmaceuticalIndustry #IndiaPharma #GlobalSupplyChain #APIs #DrugManufacturing #HealthcareInnovation #MedTech #PharmaGrowth #MakeInIndia #PLI #HealthcareStartups #DigitalHealth #Biopharma #R&D #AIinHealthcare #PharmaExports #SupplyChainResilience #HealthcareTech #Dseidehealthcarenetwork Source: Financial Express

Higher tariffs imposed by the U.S. on certain pharmaceutical imports from India are unlikely to impact the country’s competitive edge in the American market, according to industry experts. India remains a dominant player in the U.S. pharmaceutical sector, supplying around 40% of generic drugs. Factors such as cost-efficient manufacturing, a skilled workforce, and regulatory compliance continue to support India’s strong market presence. While the Biden administration has increased tariffs on some Chinese pharmaceutical ingredients, India is seen as a reliable alternative for drug production. The Indian pharmaceutical industry has also been expanding its manufacturing capabilities, reducing dependence on Chinese raw materials. This shift enhances supply chain resilience and ensures steady exports to the U.S. Industry leaders believe that India’s ability to produce affordable, high-quality medicines will help it withstand tariff changes. Additionally, ongoing investments in research and development (R&D), innovation, and adherence to U.S. FDA standards reinforce India’s position as a preferred supplier. Despite potential short-term cost pressures, Indian pharmaceutical firms are expected to remain competitive by leveraging economies of scale and focusing on high-value drug formulations. The long-term outlook remains positive, driven by global demand for affordable medicines and strong bilateral trade relations. #IndiaPharma #USPharmaMarket #GenericDrugs #PharmaExports #TradeRelations #HealthcareIndustry #MedTech #Tariffs #PharmaManufacturing #SupplyChain #AffordableMedicine #PharmaInnovation #DrugSupply #FDACertified #HealthTech #GlobalPharma #PharmaceuticalIndustry #dseidehealthcarenetwork Source: Financial Express